

WEINSTEIN MARK L  
Form 4  
February 02, 2010

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
WEINSTEIN MARK L

(Last) (First) (Middle)

C/O BIOCLINICA, INC., 826  
NEWTOWN-YARDLEY ROAD

(Street)

NEWTOWN, PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
BIOCLINICA INC [BIOC]

3. Date of Earliest Transaction  
(Month/Day/Year)  
01/29/2010

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

President & CEO

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
|                                 |                                      |  | Code                           | V   | Amount or Price   |  |   |
| Common Stock                    | 01/29/2010                           |  | M/K                            |   | 150,000<br>(1)<br>\$ 0.72   | A  | 416,176 D   |
| Common Stock                    | 01/29/2010                           |  | F/K                            |   | 29,439<br>(1)<br>\$ 4.44  | D  | 386,737 D   |
| Common Stock                    | 01/29/2010                           |  | M/K                            |   | 10,000<br>(2)<br>\$ 0.66  | A  | 396,737 D   |
| Common Stock                    | 01/29/2010                           |  | F/K                            |   | 1,833 (2)<br>\$ 4.44  | D  | 394,904 D   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |              |                      |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--------------|----------------------|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date   | Title        | Amount Number Shares |
| Option to Purchase Common Stock            | \$ 0.72  | 01/29/2010                           |  | M/K                            | 150,000<br>(1)  | 02/01/2000   | 02/01/2010  | Common Stock | 150,000              |
| Option to Purchase Common Stock            | \$ 0.66  | 01/29/2010                           |  | M/K                            | 10,000<br>(2)   | 12/31/2000   | 12/31/2010  | Common Stock | 10,000               |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |                 |       |
|---|---------------|-----------|-----------------|-------|
|   | Director      | 10% Owner | Officer         | Other |
| WEINSTEIN MARK L<br>C/O BIOCLINICA, INC.<br>826 NEWTOWN-YARDLEY ROAD<br>NEWTOWN, PA 18940 | X             |           | President & CEO |       |

## Signatures

/s/ Maria T. Kraus as attorney-in-fact  
02/02/2010

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- The sale of 29,439 shares of Common Stock held by the person is in connection with a stock swap whereby the reporting person disposed
- (1) of 29,439 shares of Common Stock to the Company as consideration for the reporting person's exercise of stock options to purchase 150,000 shares of Common Stock and to cover the withholding taxes associated with the exercise of the 150,000 shares.
  - (2) The sale of 1,833 shares of Common Stock held by the person is in connection with a stock swap whereby the reporting person disposed of 1,833 shares of Common Stock to the Company as consideration for the reporting person's exercise of stock options to purchase 10,000

## Edgar Filing: WEINSTEIN MARK L - Form 4

shares of Common Stock and to cover the withholding taxes associated with the exercise of the 10,000 shares.

(3) Includes multiple option grants with different exercise prices and vesting dates.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.